☆
4.7
Article
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
JOURNAL OF CLINICAL ONCOLOGY (2005)
评价这篇论文
主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation